Reshaping Gastroesophageal Adenocarcinoma Care: Integrating New Anti-HER2 Therapies CME/CNE/CPE/IPCE Monday, November 9, 2026 | 15:30 - 16:15 ET Virtual (++)

Reshaping Gastroesophageal Adenocarcinoma Care: Integrating New Anti-HER2 Therapies CME/CNE/CPE/IPCE Monday, November 9, 2026 | 15:30 - 16:15 ET Virtual https://na.eventscloud.com/website/99132/ Transform your gastroesophageal adenocarcinoma (GEA) practice by joining expert oncologists Elena Elimova, Samuel J. Klempner, and Kohei Shitara for an interactive, 45-minute online discussion. Unpack the latest clinical trial data for novel anti-human epidermal growth factor receptor 2 (HER2) regimens, learn how to integrate new frontline regimens into care for patients with HER2-positive GEA, and gain insight into postprogression strategies. Advancing the DLBCL Paradigm Sequencing Bispecifics in Optimizing Patient Care CME New Orleans Ernest N. Morial Convention Center Friday, December 11, 2026 | 7:30 pm - 9:00 pm CT Hybrid https://na.eventscloud.com/website/98542/ Join this engaging, interactive symposium exploring the rapidly evolving landscape of bispecific antibodies in diffuse large B-cell lymphoma (DLBCL). Leading international experts will dive into topline clinical evidence across second- and third-line settings and frontline horizons, evaluating pivotal trial data in transplant-ineligible and high-risk populations. Through real-world clinical case scenarios, the panel will debate treatment sequencing—weighing bispecifics against chimeric antigen receptor (CAR) T-cell therapy, individualizing care based on patient fitness and geographic access, and assessing impacts on T-cell fitness. Furthermore, faculty will address key practicalities for integrating bispecific therapies into community practice, from managing safety and treatment logistics to streamlining care coordination and patient pathways. Walk away with concrete solutions to optimize sequencing, safety, and care delivery across the DLBCL continuum.